PEPFAR Overhaul Puts Global Antiretroviral Supply Chain at Risk: 8.7M Patients Impacted
For biopharma manufacturers, the restructuring of PEPFAR and the September award expirations threaten high-volume procurement contracts and stable antiretroviral demand. The cliff could disrupt clinical trial infrastructure, inventory planning, and generic drug production that have relied on predictable US funding for over two decades.
Source: edition.cnn.com · cbs58.com